CorMedix (CRMD) Stock Forecast & Price Target

Cormedix is supported by DefenCath’s strong commercial execution, with $66.1M in revenue beating both estimates and management seeing steady large-customer ordering, including a new contract with the final major LDO that should reinforce durability beyond the post-TDAPA period. The company also has meaningful upside from reimbursement and market-access dynamics, as higher CMS pricing revisions, a potential $175-$195M guidance framework, and a possible lift to roughly $7-$9 in ESRD add-on payment could help sustain demand while real-world evidence later this year may strengthen payer discussions. Beyond DefenCath, the Rezzayo franchise adds diversification and a new growth leg, with $325-$345M FY26 revenue guidance, $125-$140M EBITDA guidance, and broader pipeline optionality from the 2H26 sNDA submission and expected FDA decision in 1H27.

Cormedix is facing a weak fundamental setup because DefenCath still must prove traction in hemodialysis for ESRD in an essentially new U.S. market, where cheap and established heparin solutions already dominate physician mind share. The investment case is further burdened by concentration risk with one anchor customer or MDO, pricing uncertainty tied to the TDAPA cliff in 2026, and an expansion opportunity that remains undefined while additional studies are still needed. Financially, the company is expected to continue net losses through commercialization and the early launch phase, may need dilutive capital raises, and if DefenCath or the Melinta deal fails, the stock could move closer to net cash value with minimal pipeline worth.